SLS

Company Overview — What Does SELLAS Life Sciences Group, Inc. Do?

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York. SELLAS Life Sciences Group, Inc. (SLS) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Angelos M. Stergiou and employs approximately 10 people, headquartered in Camden, New York. With a market capitalization of $756M, SLS is one of the notable companies in the Healthcare sector.

SELLAS Life Sciences Group, Inc. (SLS) Stock Rating — Reduce (April 2026)

As of April 2026, SELLAS Life Sciences Group, Inc. receives a Reduce rating with a composite score of 33.3/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SLS ranks #3,623 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, SELLAS Life Sciences Group, Inc. ranks #587 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SLS Stock Price and 52-Week Range

SELLAS Life Sciences Group, Inc. (SLS) currently trades at $4.87. The stock lost $0.18 (3.6%) in the most recent trading session. The 52-week high for SLS is $6.00, which means the stock is currently trading -18.8% from its annual peak. The 52-week low is $0.95, putting the stock 411.8% above its annual trough. Recent trading volume was 4.0M shares, reflecting moderate market activity.

Is SLS Overvalued or Undervalued? — Valuation Analysis

SELLAS Life Sciences Group, Inc. (SLS) carries a value factor score of 29/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 11.43x, versus the sector average of 2.75x.

At current multiples, SELLAS Life Sciences Group, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

SELLAS Life Sciences Group, Inc. Profitability — ROE, Margins, and Quality Score

SELLAS Life Sciences Group, Inc. (SLS) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -37.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -33.6% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SLS Debt, Balance Sheet, and Financial Health

SELLAS Life Sciences Group, Inc. has a debt-to-equity ratio of 11.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 10.72x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $44M.

SLS has a beta of 0.91, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for SELLAS Life Sciences Group, Inc. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

SELLAS Life Sciences Group, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, SELLAS Life Sciences Group, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.25. Net income for the quarter was $-26M. Operating income came in at $-27M.

In FY 2025, SELLAS Life Sciences Group, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.25. Net income for the quarter was $-27M. Operating income came in at $-28M.

In Q3 2025, SELLAS Life Sciences Group, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.06. Net income for the quarter was $-7M. Operating income came in at $-7M.

In Q2 2025, SELLAS Life Sciences Group, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.07. Net income for the quarter was $-7M. Operating income came in at $-7M.

Over the past 8 quarters, SELLAS Life Sciences Group, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing SLS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SLS Dividend Yield and Income Analysis

SELLAS Life Sciences Group, Inc. (SLS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SLS Momentum and Technical Analysis Profile

SELLAS Life Sciences Group, Inc. (SLS) has a momentum factor score of 72/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 8/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

SLS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, SELLAS Life Sciences Group, Inc. (SLS) ranks #587 out of 838 stocks based on the Blank Capital composite score. This places SLS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SLS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SLS vs S&P 500 (SPY) comparison to assess how SELLAS Life Sciences Group, Inc. stacks up against the broader market across all factor dimensions.

SLS Next Earnings Date

No upcoming earnings date has been announced for SELLAS Life Sciences Group, Inc. (SLS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SLS? — Investment Thesis Summary

The quantitative profile for SELLAS Life Sciences Group, Inc. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 29/100 indicates premium valuation. Price momentum is positive at 72/100, suggesting the trend favors buyers. High volatility (stability score 35/100) increases portfolio risk.

In summary, SELLAS Life Sciences Group, Inc. (SLS) earns a Reduce rating with a composite score of 33.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SLS stock.

Related Resources for SLS Investors

Explore more research and tools: SLS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SLS head-to-head with peers: SLS vs AZN, SLS vs SLGL, SLS vs VMD.